Randomised, split‐face study of a dermocosmetic cream containing Sphingobioma xenophaga extract and Neurosensine® in subjects with rosacea associated with erythema and sensitive skin

Enzo Berardesca,Claudia Cartigliani,Margot Nioré,Adriana Bonfigli,Ludivine Canchy,Delphine Kerob,Jerry Tan
DOI: https://doi.org/10.1111/srt.13735
2024-06-22
Skin Research and Technology
Abstract:Introduction Rosacea is a chronic inflammatory skin condition associated with erythema, inflammation and skin sensitivity. Objectives To assess the benefit of a dermocosmetic cream (DC cream) containing Sphingobioma xenophaga extract and soothing agent in adult females with rosacea‐associated erythema and sensitive skin. Materials and Methods During phase 1, DC was applied twice daily on the randomized half‐face and compared to usual‐skincare (USC) for 28 days. During phase 2, DC was applied on the full face twice daily for 56 days. Clinical, instrumental and skin sensitivity assessments were performed at all visits; demodex density (standardized skin surface biopsy (SSSB) method) was performed at baseline and D28, quality of life (QoL) was assessed using the stigmatization questionnaire (SQ), Rosacea Quality of Life index (ROSAQoL) and Dermatology Life Quality Index (DLQI) at baseline and D84. Results At D28, a significant benefit of DC over USC was observed for erythema, tightness, burning and stinging (all p ≤ 0.05), erythema measured by chromameter (p
dermatology
What problem does this paper attempt to address?